Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Molecular signatures and prognosis of hepatocellular carcinoma.

Hoshida Y.

Minerva Gastroenterol Dietol. 2011 Sep;57(3):311-22.

PMID:
21769080
2.

Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis.

Yamazaki K, Masugi Y, Sakamoto M.

Dig Dis. 2011;29(3):284-8. doi: 10.1159/000327560. Epub 2011 Aug 9. Review.

3.

Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.

Coulouarn C, Factor VM, Thorgeirsson SS.

Hepatology. 2008 Jun;47(6):2059-67. doi: 10.1002/hep.22283.

4.

The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma.

Ikeguchi M, Iwamoto A, Taniguchi K, Katano K, Hirooka Y.

J Exp Clin Cancer Res. 2005 Sep;24(3):415-21.

PMID:
16270528
5.
6.

Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter.

Sohn BH, Park IY, Lee JJ, Yang SJ, Jang YJ, Park KC, Kim DJ, Lee DC, Sohn HA, Kim TW, Yoo HS, Choi JY, Bae YS, Yeom YI.

Gastroenterology. 2010 May;138(5):1898-908. doi: 10.1053/j.gastro.2009.12.044. Epub 2009 Dec 29.

PMID:
20038433
7.

Differential promoter usage for insulin-like growth factor-II gene in Chinese hepatocellular carcinoma with hepatitis B virus infection.

Tang SH, Yang DH, Huang W, Zhou M, Zhou HK, Lu XH, Ye G.

Cancer Detect Prev. 2006;30(2):192-203. Epub 2006 May 12.

PMID:
16697535
8.
9.

Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma.

Ivanovska I, Zhang C, Liu AM, Wong KF, Lee NP, Lewis P, Philippar U, Bansal D, Buser C, Scott M, Mao M, Poon RT, Fan ST, Cleary MA, Luk JM, Dai H.

PLoS One. 2011;6(9):e24582. doi: 10.1371/journal.pone.0024582. Epub 2011 Sep 16.

10.

Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease.

Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu MA, Daino L, Sanna V, Feo F, Pascale RM.

Carcinogenesis. 2008 Aug;29(8):1639-47. doi: 10.1093/carcin/bgn155. Epub 2008 Jun 25.

11.

[Comparative genomic classification of human hepatocellular carcinoma].

Kaposi-Novák P.

Magy Onkol. 2009 Mar;53(1):61-7. doi: 10.1556/MOnkol.53.2009.1.9. Hungarian.

12.

Specific molecular markers in hepatocellular carcinoma.

Yao DF, Dong ZZ, Yao M.

Hepatobiliary Pancreat Dis Int. 2007 Jun;6(3):241-7. Review.

13.

Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.

Torbenson M, Marinopoulos S, Dang DT, Choti M, Ashfaq R, Maitra A, Boitnott J, Wilentz RE.

Hum Pathol. 2002 Sep;33(9):871-6.

PMID:
12378510
14.

Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence.

Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, Lau GK, Beretta L, Fan ST.

Mol Cell Proteomics. 2008 Feb;7(2):315-25. Epub 2007 Oct 14.

15.

A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma.

Schröder PC, Segura V, Riezu JI, Sangro B, Mato JM, Prieto J, Santamaría E, Corrales FJ.

Funct Integr Genomics. 2011 Sep;11(3):419-29. doi: 10.1007/s10142-011-0230-7. Epub 2011 May 12.

PMID:
21562899
16.

Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma.

Abou-Shady M, Baer HU, Friess H, Berberat P, Zimmermann A, Graber H, Gold LI, Korc M, Büchler MW.

Am J Surg. 1999 Mar;177(3):209-15.

PMID:
10219856
17.

Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.

Zondervan PE, Wink J, Alers JC, IJzermans JN, Schalm SW, de Man RA, van Dekken H.

J Pathol. 2000 Oct;192(2):207-15.

PMID:
11004697
18.

ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.

Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, Lai PL, Hsu HC.

Clin Cancer Res. 2008 Aug 1;14(15):4814-20. doi: 10.1158/1078-0432.CCR-07-5262.

19.
20.

Clinicopathologic and gene expression parameters predict liver cancer prognosis.

Hao K, Lamb J, Zhang C, Xie T, Wang K, Zhang B, Chudin E, Lee NP, Mao M, Zhong H, Greenawalt D, Ferguson MD, Ng IO, Sham PC, Poon RT, Molony C, Schadt EE, Dai H, Luk JM.

BMC Cancer. 2011 Nov 9;11:481. doi: 10.1186/1471-2407-11-481.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk